• Sourcing Solutions
  • Services & Membership
  • Help & Community

Quick Details

  • Classification: Phosphate
  • Type: Sodium Phosphate
  • CAS No.: 10163-15-2
  • Other Names: MFP
  • MF: FNa2O3P
  • EINECS No.: 233-433-0
  • Place of Origin: Shaanxi, China (Mainland)
  • Grade Standard: Industrial Grade, Medicine Grade, Reagent Grade
  • Purity: 99%
  • Appearance: white powder
  • Application: an ingredient in toothpastes industry
  • Brand Name: Top Pharm Chem
  • Model Number: TOPVT0113

Packaging & Delivery

Packaging Details 25kg/bag
Delivery Time In stock, immediately
 
Product Description

  

Sodium Monofluorophosphate

 

Sodium monofluorophosphate, commonly abbreviated MFP, is the inorganic compound with the formula Na2PO3F. Typical for a salt, MFP is odourless, colourless, and water-soluble. This salt is an ingredient in some toothpastes.

 

Uses of MFP

 

MFP is best known as an ingredient in toothpastes. It is claimed to protect tooth enamel from attack by bacteria that cause dental caries (cavities). Though developed by a chemist at Procter and Gamble, its use in toothpaste (Colgate toothpaste) was patented by Colgate-Palmolive, as Procter and Gamble was engaged in the marketing of Crest toothpaste (containing stannous fluoride, marketed as "Fluoristan"). In the early 1980s, Crest was reformulated to use MFP, under the trademark "Fluoristat"; today Crest toothpastes use sodium fluoride.

 

MFP is also used in some medications for the treatment of osteoporosis.

 

In 1991, sodium monofluorophosphate was found by Calgon to inhibit the dissolution of lead in drinking water when used in concentrations between 0.1 mg/L and 500 mg/L.

 

Tooth decay

 

Tooth decay is caused by bacteria naturally present in one's mouth. These bacteria form a sticky, colorless soft film on the teeth called plaque. When foods containing carbohydrates (starches and sugars) are eaten, the bacteria that form plaque use the sugar as a form of energy. They also turn it into a glue-like substance that helps them stick to the surface of the tooth. The plaque produces acid, which attacks the enamel.

 

Chemistry of decay

 

Tooth enamel consists mostly of calcium hydroxyphosphate, Ca5(PO4)3OH, also known as the mineral hydroxyapatite. Apatite is a hard, insoluble compound. Acid (H+), produced especially after a high-sugar meal, attacks the apatite:

 

Ca5(PO4)3OH(s) + H+(aq) → Ca5(PO4)3+(aq) + H2O

 

Chemistry of enamel fluoridation

 

The degradation of apatite by loss of OH− causes the enamel to dissolve. The process is reversible as saliva supplies back OH− to reform apatite. If fluoride, F−, ions are present in saliva, fluorapatite, Ca5(PO4)3F, also forms.

 

Ca5(PO4)3+(aq) + F−(aq) → Ca5(PO4)3F(s)

 

Fluorapatite resists attacks by acids better than apatite itself, so the tooth enamel resists decay better than enamel containing no fluoride.

 

Preparation

 

MFP is prepared by hydrolysis of difluorophosphate ions with dilute sodium hydroxide:

 

PO2F2− + 2 NaOH → Na2PO3F + H2O + F−

Discovery and development

 

Sodium monofluorophosphate was first described in 1929 by the German chemist Willy Lange, who was then with the University of Berlin. His fruitless attempts to prepare the free monofluorophosphoric acid led him to check the stability of its esters. Together with Gerda von Krueger, one of his students, Lange thus synthesized diethyl fluorophosphate and some analogs, which proved to be quite toxic, being related to nerve agents. In the 1930s, Gerhard Schrader, working for the German company IG Farben, tried to develop synthetic insecticide. His work focused on esters of phosphoric acid and resulted in an accidental discovery of some other nerve agents such as DFP (diisopropyl fluorophosphate), Tabun, Soman, and Sarin. In the meantime, Lange, who was married to a Jewish woman, emigrated from Germany to the United States and started work for Procter and Gamble Company. In 1947, he and Ralph Livingston of Monsanto Company published the preparation of the free fluorophosphoric acids and mentioned the use of some toxic esters of monofluorophosphoric acid (like DFP) in the treatment of glaucoma and myasthenia gravis. The well known toxicity of these esters led to fears that the simple salts might also be toxic, and such fears precluded any large scale commercial use of the salts. In 1950, under sponsorship of the manufacturer of the compounds, Ozark Chemical Company, the toxicity of sodium monofluorophosphate was studied by Harold Hodge at the University of Rochester who included anti-cavity testing. In 1967 Colgate-Palmolive filed several patents on the use of sodium monofluorophosphate in toothpaste.

 

Content and toxicity

 

The usual content of MFP in toothpaste is 0.76%. Currently accepted research[dubious – discuss] indicates that by using such toothpaste, cavities may be reduced 17–38%.[citation needed] The compound is not very toxic but has been shown to have limited evidence of musculoskeletal and respiratory toxicities.The LD50 in rats is 0.9 g/kg.

 

Structure of fluorophosphate

 

The structure of the fluorophosphate anion consists of phosphorus at the center of a tetrahedron defined by three oxygen atoms and one fluorine. Formal representations depict a double bond between one oxygen atom and phosphorus, with single bonds for the other two oxygen atoms and the fluorine. In this very formal depiction, negative charge is localized on the O atoms of the single P-O bonds. MFP is similar to and isoelectronic with Na2SO4.

Discovery and development

 

Sodium monofluorophosphate was first described in 1929 by the German chemist Willy Lange, who was then with the University of Berlin. His fruitless attempts to prepare the free monofluorophosphoric acid led him to check the stability of its esters. Together with Gerda von Krueger, one of his students, Lange thus synthesized diethyl fluorophosphate and some analogs, which proved to be quite toxic, being related to nerve agents. In the 1930s, Gerhard Schrader, working for the German company IG Farben, tried to develop synthetic insecticide. His work focused on esters of phosphoric acid and resulted in an accidental discovery of some other nerve agents such as DFP (diisopropyl fluorophosphate), Tabun, Soman, and Sarin. In the meantime, Lange, who was married to a Jewish woman, emigrated from Germany to the United States and started work for Procter and Gamble Company. In 1947, he and Ralph Livingston of Monsanto Company published the preparation of the free fluorophosphoric acids and mentioned the use of some toxic esters of monofluorophosphoric acid (like DFP) in the treatment of glaucoma and myasthenia gravis. The well known toxicity of these esters led to fears that the simple salts might also be toxic, and such fears precluded any large scale commercial use of the salts. In 1950, under sponsorship of the manufacturer of the compounds, Ozark Chemical Company, the toxicity of sodium monofluorophosphate was studied by Harold Hodge at the University of Rochester who included anti-cavity testing. In 1967 Colgate-Palmolive filed several patents on the use of sodium monofluorophosphate in toothpaste.

 

Content and toxicity

 

The usual content of MFP in toothpaste is 0.76%. Currently accepted research[dubious – discuss] indicates that by using such toothpaste, cavities may be reduced 17–38%.[citation needed] The compound is not very toxic but has been shown to have limited evidence of musculoskeletal and respiratory toxicities.The LD50 in rats is 0.9 g/kg.

 

Structure of fluorophosphate

 

The structure of the fluorophosphate anion consists of phosphorus at the center of a tetrahedron defined by three oxygen atoms and one fluorine. Formal representations depict a double bond between one oxygen atom and phosphorus, with single bonds for the other two oxygen atoms and the fluorine. In this very formal depiction, negative charge is localized on the O atoms of the single P-O bonds. MFP is similar to and isoelectronic with Na2SO4.

 

 

 

FAQ 

 

Any new application for MFP?

 

Treatment of vertebral osteoporosis with disodium monofluorophosphate: comparison with sodium fluoride.

 

Eighty one women with vertebral osteoporosis were treated for up to 2 years with fluoride administered either as monofluorophosphate (MFP, 200 mg/day, i.e., 26.4 mg fluoride-ion) or sodium fluoride (NaF, 50 mg/day, i.e., 22.6 mg fluoride-ion). All patients received calcium supplementation (1 g of Ca2+/day) taken apart from NaF and in the same tablet for MFP. Despite almost similar fluoride dosage of both regimens, the early increase in the bone mineral density (BMD) of the lumbar spine was higher with MFP than with NaF, reaching 11% and 4%, respectively, at 1 year (p = 0.007), and 21% and 6%, respectively, at 18 months (p less than 0.001). The incidence of lower extremity pain syndrome related to benign stress microfractures was also higher with MFP than with NaF (35% and 15%, respectively, p less than 0.01). Urinary fluoride levels were higher in the MFP than in the NaF group (9.6 +/- 3.5 vs. 6.8 +/- 3.4 at one year, p = 0.003), suggesting that this difference in efficacy and tolerance is related to a better bioavailability of fluoride provided by MFP than by NaF. The occurrence of a stress microfracture could not be predicted by any clinical, biochemical, or densitometric parameter before treatment, but patients presenting with a stress microfracture during the course of the treatment had a higher gain in bone mass than those without stress fractures (at 1 yr+11 vs. +5%, p = 0.03 and at 18 months +18 vs. +6.9%, p less than 0.02). In conclusion, there is a clear correlation between the efficacy and the occurrence of side effects of fluoride therapy in osteoporosis.

 
Packaging & Shipping

  

Our normal packaging is 25kg/drum or box or bag. The shipping term can be by sea, by air, your other express company like DHL, FEDEX, EMS, and TNT.

 
Our Services

 

a) Free sample can be supplied.

b) Guide our clients by professinal techniques and teach them how to use our product after sales

c) Define lowest price on quality products.

 

 

 

Company Information

Shaanxi Top Pharm Chemical Co., Ltd. has been primarily engaged in the research, development, and marketing of various photochemical products since 1999. We take full advantages of natural pharmaceutical resources

which grow in the areas of Qinba Mountain and Qinling Mountain. Within years' development, our core competitiveness has been firmly formed and developed.  

At Top Pharm, we devoted ourselves to the sophisticated products with carefully selected natural resources to meet the demands' of our customers in advance.

 Our detailed business scope:

 1. Extract/sap and separated effective components from natural plants

2. Supplying amino acid/aminophenol & vitamin series of products

3. Identifying the quality of medicine raw materials

4. Developing the newest pharmaceutical intermediates

5. Providing functional ingredients

 At Top Pharm, we firmly believe that customers' success is our success. Each staff member of our company is devoted to being ready for your requirements.

 

Transaction History of the Supplier

Below is the information about the supplier's transactions conducted via Alibaba.com. If you require further details regarding the transaction data, please contact the supplier directly.

Transaction Overview

Transactions

Transaction Details

This supplier has completedtransactions with buyers from .

Shipping Destination
Transaction Value
Transaction Date
Email to this supplier
China (Mainland) | Manufacturer, Trading Company
Transaction Level:
Supplier Assessments:
The supplier supports Trade Assurance – A free service that protects your orders from payment to delivery.
Supplier's Trade Assurance Limit: US $33,000
Learn More